Universe Pharmaceuticals (UPC) Cash & Equivalents (2020 - 2025)

Universe Pharmaceuticals has disclosed Cash & Equivalents across 6 years of filings, most recently posting $70.2 million for Q3 2025.

• Cash & Equivalents for Q3 2025 came in at $70.2 million, down 99.76% year-over-year; the trailing twelve-month figure through Sep 2025 was $70.2 million (down 99.76% YoY), and the FY2025 annual result was $70.2 million, down 99.76% from the prior year.
• Cash & Equivalents came in at $70.2 million for Q3 2025 at Universe Pharmaceuticals, down from $29.5 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $29.5 billion in Q3 2024 to a low of $8.1 million in Q3 2021.
• The 5-year median for Cash & Equivalents is $42.2 million (2022), against an average of $5.1 billion.
• Across the five-year window, Cash & Equivalents soared 70604.67% in 2022 and plunged 99.76% in 2025, its largest moves.
• Universe Pharmaceuticals' Cash & Equivalents stood at $8.1 million in 2021, then jumped by 70604.67% to $5.7 billion in 2022, then fell by 7.46% to $5.3 billion in 2023, then jumped by 458.11% to $29.5 billion in 2024, then slumped by 99.76% to $70.2 million in 2025.
• The last three Cash & Equivalents figures came in at $70.2 million (Q3 2025), $29.5 billion (Q3 2024), and $8.9 million (Q1 2024), per Business Quant data.